Thus, dual inhibition of STAT3 and NF-κB by EC-70124 impairs CSC maintenance and tumor development in mice and provides the basis for new therapeutic strategies for treatment of prostate cancer. This evidence concerns the gene NFKB1 and prostate carcinoma.